Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gres, DM, Meyer LR. AJCC Cancer Staging Manual. Ed. 8 Cham, Switzerland: Springer; 2017.
Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
Kankaya D. Current Status of Histologic Grading in Prostate Carcinoma and Renal Cell Carcinoma. J Urol Surg 2017;4:102-105.
Bonsib SM. Renal veins and venous extension in clear cell renal cell carcinoma. Mod Pathol 2007;20:44-53.
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490–1504.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:1240-1267.
Paner GP, Montironi R, Amin MB. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol 2017;24:113-127.
Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ, Kassouf W. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 2013;44:95-102.
Hu Z, Mudaliar K, Quek ML, Paner GP, Barkan GA. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol 2014;18:49-52.
van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-384.
Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol 2003;169:149-152.
Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen SC, Groshen S, Simoneau A, Skinner EC, Lieskovsky G, Boyd SD, Cote RJ, Skinner DG. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996;156:1071-1076.
Pagano F, Bassi P, Ferrante GL, Piazza N, Abatangelo G, Pappagallo GL, Garbeglio A. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 1996;155:244-247.
Patel AR, Cohn JA, Abd El Latif A, Miocinovic R, Steinberg GD, Paner GP, Hansel DE. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma. J Urol 2013;189:53-58.
Knoedler JJ, Boorjian SA, Tollefson MK, Cheville JC, Thapa P, Tarrell RF, Frank I. Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy. BJU Int 2014;114:832-836.
Hansel DE, Paner GP, Nese N, Amin MB. Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. Hum Pathol 2011;42:1770-1776.
Tamas EF, Stephenson AJ, Campbell SC, Montague DK, Trusty DC, Hansel DE. Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med 2009;133:791–796.
Hu B, Satkunasivam R, Schuckman A, Miranda G, Cai J, Daneshmand S Urothelial carcinoma in bladder diverticula: outcomes after radical cystectomy. World J Urol 2015;33:1397–1402.
Leissner J, Ghoneim MA, Abol-Enein H, Thüroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, el-Baz MA, Kastendieck H, Buhtz P, Kropf S, Hohenfellner R, Wolf HK. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004;171:139-144.
Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 2004;171:1830-1834.
van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24:16-25.
Verrill C, Perry-Keene J, Srigley JR, Zhou M, Humphrey PA, Lopez-Beltran A, Egevad L, Ulbright TM, Tickoo SK, Epstein JI, Compérat E, Berney DM; Members of the ISUP Testicular Tumor Panel. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol 2018;42:e33-e43.
Brimo F, Srigley SR, Ryan RJ, Choyke PL, Ryan CJ, Humphrey PA, Barocas DA, Brookland RK,BuyyounouskiMK, Fine SW, Halabi S, Hamstra DA, Kattan MW, McKenney JK, Mason MD, Oh WK, Pettaway CA, Touijer KA,Zelefsky MJ, Sandler HM, Lin DW, Amin MB. Chapter 59: Testis. In: Amin MB, Edge SB, Greene F, eds. AJCC Cancer Staging Manual, 8th ed. Chicago, IL: American Joint Committee on Cancer; 2017.
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-569.
Chung P, Daugaard G, Tyldesley S, Atenafu EG, Panzarella T, Kollmannsberger C, Warde P. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med 2015:4:155-160.
Cohn-Cedermark G, Stahl O, Tandstad T; SWENOTECA. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology 2015;3:102-110.
Coursey Moreno C, Small WC, Camacho JC, Master V, Kokabi N, Lewis M, Hartman M, Mittal PK. Testicular tumors: what radiologists need to know--differential diagnosis, staging, and management. Radiographics 2015;35:400-415.
Dry SM, Renshaw AA. Extratesticular extension of germ cell tumors preferentially occurs at the hilum. AmJ Clin Pathol 1999;111:534-538.
Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014.
Sun M, Djajadiningrat RS, Alnajjar HM, Trinh QD, Graafland NM, Watkin N, Karakiewicz PI, Horenblas S. Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU Int 2015;116:734-743.
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2013;11:594-615.
Velazquez EF, Ayala G, Liu H, Chaux A, Zanotti M, Torres J, Cho SI, Barreto JE, Soares F, Cubilla AL. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008;32:974-979.
Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol 2008;180:933-938.
Li ZS, Yao K, Chen P, Wang B, Chen JP, Mi QW, Li YH, Liu ZW, Qin ZK, Zhou FJ, Han H. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer 2015;113:1746.
. Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL. New N staging system of penile cancer provides a better reflection of prognosis. J Urol 2011;186:518523.
. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015;67:142-150.
Broders AC. Squamous-cell epithelioma of the skin: a study of 256 cases. Ann Surg 1921;73:141-160.
Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL. Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol 2005;29:1152-1158.

APA	ALTAY C, MUTLU U, Demir O, YÖRÜKOĞLU K, CANDA A, SEÇİL M (2018). Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. , 140 - 142. 10.4274/jus.1998
Chicago	ALTAY Canan,MUTLU Uygar,Demir Omer,YÖRÜKOĞLU Kutsal,CANDA Aras Emre,SEÇİL Mustafa Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. (2018): 140 - 142. 10.4274/jus.1998
MLA	ALTAY Canan,MUTLU Uygar,Demir Omer,YÖRÜKOĞLU Kutsal,CANDA Aras Emre,SEÇİL Mustafa Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. , 2018, ss.140 - 142. 10.4274/jus.1998
AMA	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. . 2018; 140 - 142. 10.4274/jus.1998
Vancouver	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. . 2018; 140 - 142. 10.4274/jus.1998
IEEE	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M "Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma." , ss.140 - 142, 2018. 10.4274/jus.1998
ISNAD	ALTAY, Canan vd. "Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma". (2018), 140-142. https://doi.org/10.4274/jus.1998

APA	ALTAY C, MUTLU U, Demir O, YÖRÜKOĞLU K, CANDA A, SEÇİL M (2018). Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. Journal of Urological Surgery, 5(2), 140 - 142. 10.4274/jus.1998
Chicago	ALTAY Canan,MUTLU Uygar,Demir Omer,YÖRÜKOĞLU Kutsal,CANDA Aras Emre,SEÇİL Mustafa Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. Journal of Urological Surgery 5, no.2 (2018): 140 - 142. 10.4274/jus.1998
MLA	ALTAY Canan,MUTLU Uygar,Demir Omer,YÖRÜKOĞLU Kutsal,CANDA Aras Emre,SEÇİL Mustafa Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. Journal of Urological Surgery, vol.5, no.2, 2018, ss.140 - 142. 10.4274/jus.1998
AMA	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. Journal of Urological Surgery. 2018; 5(2): 140 - 142. 10.4274/jus.1998
Vancouver	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma. Journal of Urological Surgery. 2018; 5(2): 140 - 142. 10.4274/jus.1998
IEEE	ALTAY C,MUTLU U,Demir O,YÖRÜKOĞLU K,CANDA A,SEÇİL M "Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma." Journal of Urological Surgery, 5, ss.140 - 142, 2018. 10.4274/jus.1998
ISNAD	ALTAY, Canan vd. "Magnetic Resonance Imaging Features of Prostate Mucinous Adenocarcinoma". Journal of Urological Surgery 5/2 (2018), 140-142. https://doi.org/10.4274/jus.1998